Heart failure in African Americans: Earlier onset, different etiologies, and poorer prognosis

[1]  Anne L. Taylor,et al.  Isosorbide dinitrate and hydralazine in a fixed-dose combination produces further regression of left ventricular remodeling in a well-treated black population with heart failure: results from A-HeFT. , 2007, Journal of cardiac failure.

[2]  Anne L. Taylor,et al.  Early and Sustained Benefit on Event-Free Survival and Heart Failure Hospitalization From Fixed-Dose Combination of Isosorbide Dinitrate/Hydralazine: Consistency Across Subgroups in the African-American Heart Failure Trial , 2007, Circulation.

[3]  Kevin L. Thomas,et al.  Racial differences in the characteristics of patients admitted for acute decompensated heart failure and their relation to outcomes: results from the OPTIME-CHF trial. , 2006, Journal of cardiac failure.

[4]  Anne L. Taylor,et al.  Aldosterone synthase promoter polymorphism predicts outcome in African Americans with heart failure: results from the A-HeFT Trial. , 2006, Journal of the American College of Cardiology.

[5]  R. Beyth,et al.  Racial variations in quality of care and outcomes in an ambulatory heart failure cohort. , 2006, American heart journal.

[6]  C. Yancy.  Heart failure in African Americans. , 2005, The American journal of cardiology.

[7]  J. Ornato,et al.  ACC/AHA 2005 Guideline Update for the Diagnosis and Management of Chronic Heart Failure in the Adult—Summary Article , 2005 .

[8]  Ralph D'Agostino,et al.  Combination of isosorbide dinitrate and hydralazine in blacks with heart failure. , 2004, The New England journal of medicine.

[9]  S. Goldstein.  Beta Blocker Therapy in African American Patients with Heart Failure , 2004, Heart Failure Reviews.

[10]  Anita Deswal,et al.  Impact of race on health care utilization and outcomes in veterans with congestive heart failure. , 2004, Journal of the American College of Cardiology.

[11]  S. Gottlieb,et al.  Metoprolol CR/XL in black patients with heart failure (from the Metoprolol CR/XL randomized intervention trial in chronic heart failure). , 2003, The American journal of cardiology.

[12]  H. Krumholz,et al.  Race, quality of care, and outcomes of elderly patients hospitalized with heart failure. , 2003, JAMA.

[13]  Paul G Shekelle,et al.  Efficacy of angiotensin-converting enzyme inhibitors and beta-blockers in the management of left ventricular systolic dysfunction according to race, gender, and diabetic status: a meta-analysis of major clinical trials. , 2003, Journal of the American College of Cardiology.

[14]  S. Kardia,et al.  Synergistic Polymorphisms of β1- and α2C-Adrenergic Receptors and the Risk of Congestive Heart Failure , 2002 .

[15]  M. Domanski,et al.  A trial of the beta-blocker bucindolol in patients with advanced chronic heart failure. , 2001, The New England journal of medicine.

[16]  M. Domanski,et al.  Lesser response to angiotensin-converting-enzyme inhibitor therapy in black as compared with white patients with left ventricular dysfunction. , 2001, The New England journal of medicine.

[17]  C. Yancy,et al.  Race and the response to adrenergic blockade with carvedilol in patients with chronic heart failure. , 2001, The New England journal of medicine.

[18]  J. Cohn,et al.  Racial differences in response to therapy for heart failure: analysis of the vasodilator-heart failure trials. Vasodilator-Heart Failure Trial Study Group. , 1999, Journal of cardiac failure.

[19]  K. Grumbach,et al.  Congestive heart failure hospitalizations and survival in California: patterns according to race/ethnicity. , 1999, American heart journal.

[20]  B. Gersh,et al.  Racial differences in the outcome of left ventricular dysfunction. , 1999, The New England journal of medicine.

[21]  S. Yusuf,et al.  Natural history and patterns of current practice in heart failure , 1993 .

[22]  F. Tristani,et al.  A comparison of enalapril with hydralazine-isosorbide dinitrate in the treatment of chronic congestive heart failure. , 1991, The New England journal of medicine.